Dihydropyrimidinone Based Chromones as New α‐Glucosidase Inhibitors

Abstract This study assesses newly synthesized chromones with a 3,4‐dihydropyrimidin‐2(1H)‐one core at C‐3, combined with triazole derivatives for their antidiabetic potential. Compounds 5a and 5b showed strong inhibition of α‐glucosidase, with IC 50 values of 58.99 ± 4.15 nmol and 49.18 ± 2.18 nmol. Docking studies indicated effective binding within the active site of α‐glucosidase (−10.7 kcal/mol for 5a and −10.9 kcal/mol for 5b). Computational assessments suggested both compounds have favorable profiles for drug‐likeness, ADME, and toxicity, highlighting their potential as therapeutic agents for diabetes.